VAX 014
Alternative Names: VAX-014Latest Information Update: 27 Nov 2023
At a glance
- Originator Vaxiion Therapeutics
- Class Antineoplastics; Gene therapies; Immunotherapies; Oncolytic viruses; Recombinant proteins
- Mechanism of Action Apoptosis stimulants; Cell death stimulants; Immunologic cytotoxicity
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Bladder cancer; Solid tumours
Most Recent Events
- 02 Nov 2023 Phase-I clinical trials in Solid tumours (Late-stage disease, Second-line therapy or greater) in USA (Intratumoural) (NCT05901285)
- 01 Mar 2023 VAX 014 is still in phase I trials in Bladder cancer in USA (Intravesicular) (NCT03854721)
- 01 Mar 2023 Vaxiion Therapeutics completes a phase I trial in Bladder cancer in USA (Intravesicular) (NCT03854721)